{
    "nctId": "NCT01084876",
    "briefTitle": "Demonstrate Efficacy and Safety of Metastatic Breast Cancer",
    "officialTitle": "A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination With Paclitaxel, in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 475,
    "primaryOutcomeMeasure": "Objective Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Are females\n* Have a Her 2 over-expression\n* Have ECOG 0 or 1\n\nExclusion Criteria:\n\n* Current clinical or radiographic evidence CNS metastases\n* Current Known infection\n* Pregnant or nursing mother",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}